Vivos Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
31/03/2025 23:31
Vivos Therapeutics Inc VVOS.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-3.05. The mean expectation of two analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -43 cents to -36 cents per share. Revenue rose 13.9% to $3.70 million from a year ago; analysts expected $3.89 million. Vivos Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents. The company reported a quarterly loss of $2.81 million. Vivos Therapeutics Inc shares had fallen by 27.5% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" Wall Street's median 12-month price target for Vivos Therapeutics Inc is $6.30 This summary was machine generated from LSEG data March 31 at 10:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.39 | -0.28 | Beat |
| Sep. 30 2024 | -0.61 | -0.40 | Beat |
| Jun. 30 2024 | -1.05 | -0.60 | Beat |
| Mar. 31 2024 | -1.17 | -1.63 | Missed |
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth